SNO 2020: The IMA950/Poly-ICLC Multipeptide Vaccine, With or Without Pembrolizumab, Has Elicited T-Cell Responses in Relapsed GBM
The trial is underway and patient accrual is not yet complete.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.